U.S. Markets closed

Today's Research Reports on Nuvo Pharmaceuticals, Aurinia Pharmaceuticals, Microbix Biosystems and Canopy Growth

NEW YORK, NY / ACCESSWIRE / October 23, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://rdinvesting.com and get exclusive access to our numerous research reports and market updates.

RDI Initiates Coverage on:

Nuvo Pharmaceuticals Inc.
https://rdinvesting.com/news/?ticker=NRI.TO

Aurinia Pharmaceuticals Inc.
https://rdinvesting.com/news/?ticker=AUP.TO

Microbix Biosystems Inc.
https://rdinvesting.com/news/?ticker=MBX.TO

Canopy Growth Corporation
https://rdinvesting.com/news/?ticker=WEED.TO

Nuvo Pharmaceuticals’ stock jumped 3.27% Monday, to close the day at $2.84. The stock recorded a trading volume of 2,178 shares, which was below its three months average volume of 10,998 shares. In the last year, Nuvo Pharmaceuticals' shares have traded in a range of 2.55 - 4.23. The share price has gained 11.37% from its 52 week low. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $2.76 is lower than its 200-day moving average of $2.88. Shares of the company are trading at a Price to Earnings ratio of 71.00. Shares of Nuvo Pharmaceuticals have fallen approximately 23.24 percent year-to-date.

Access RDI's Nuvo Pharmaceuticals Inc. Research Report at:
https://rdinvesting.com/news/?ticker=NRI.TO

On Monday, shares of Aurinia Pharmaceuticals recorded a trading volume of 28,417 shares, which was below the three months average volume of 33,532 shares. The stock ended the day 2.88% lower at $7.09. The share price has fallen 18.03% from its 52 week high with a 52 week trading range of 5.68 - 8.65. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $7.59 is greater than its 200-day moving average of $7.34. Shares of Aurinia Pharmaceuticals have gained approximately 23.95 percent year-to-date.

Access RDI's Aurinia Pharmaceuticals Inc. Research Report at:
https://rdinvesting.com/news/?ticker=AUP.TO

Microbix Biosystems’ stock had no change Monday, to close the day at $0.22. The stock recorded a trading volume of 39,000 shares, which was below its three months average volume of 57,327 shares. In the last year, Microbix Biosystems' shares have traded in a range of 0.21 - 0.35. The share price has gained 4.76% from its 52 week low. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $0.24 is lower than its 200-day moving average of $0.27. Shares of Microbix Biosystems have fallen approximately 29.03 percent year-to-date.

Access RDI's Microbix Biosystems Inc. Research Report at:
https://rdinvesting.com/news/?ticker=MBX.TO

On Monday, shares of Canopy Growth recorded a trading volume of 7,166,257 shares, which was above the three months average volume of 6,489,203 shares. The stock ended the day 11.16% lower at $54.46. The share price has fallen 28.98% from its 52 week high with a 52 week trading range of 12.65 - 76.68. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $64.94 is greater than its 200-day moving average of $43.73. Shares of Canopy Growth have gained approximately 83.12 percent year-to-date.

Access RDI's Canopy Growth Corporation Research Report at:
https://rdinvesting.com/news/?ticker=WEED.TO

Our Actionable Research on Nuvo Pharmaceuticals Inc. (TSX : NRI.TO ), Aurinia Pharmaceuticals Inc. (TSX : AUP.TO ), Microbix Biosystems Inc. (TSX : MBX.TO ) and Canopy Growth Corporation (TSX : WEED.TO ) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com